Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Peter Barrett‐Lee(Velindre Cancer Centre), Mark Verrill(Newcastle upon Tyne Hospitals NHS Foundation Trust), Chris Plummer(Newcastle upon Tyne Hospitals NHS Foundation Trust), N. Murray(Cancer Research UK), Carlo Palmieri(University of Liverpool), Alison Jones(Roche (Switzerland)), J. Michael Dixon(NHS Lothian), Andrew Stanley(Birmingham City Hospital), C. Farrell(The Christie NHS Foundation Trust), Renaud Léonard
Cited by 198
Related Papers
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
|Journal of Clinical Oncology|2009|850
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
|BMC Cancer|2010|755
Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals
|Journal of Clinical Oncology|2005|278
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
|PubMed|1995|239
The Parallel Rural Community Curriculum: an integrated clinical curriculum based in rural general practice
|Medical Education|2000|222